Atogepant
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Atogepant and local guidelines before prescribing.
CGRP antagonist
Mechanism
Oral CGRP receptor antagonist.
Uses
Migraine prophylaxis.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Nausea, constipation, fatigue.
Interactions
Strong CYP3A4 inhibitors raise levels.
Contraindications and cautions
Severe hepatic impairment
Monitoring
Migraine diary
Pregnancy and breastfeeding
Avoid
Renal and hepatic impairment
Avoid in severe hepatic impairment
Overdose and reversal
Supportive
Special advice
Dose-reduce with interactions.
More from the textbook: uses, cautions and other points
- CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab) and atogepant or rimegepant - after 3 preventive drugs have failed (NICE TAs; specialist).
Neurology: Anatomy, Physiology and Pharmacology - Gepants for prevention - rimegepant (TA906) and atogepant (TA973) tablets.
Neurology: Headache and Facial Pain - NICE TA260 (botulinum toxin), TA631, TA659, TA682, TA871 (CGRP antibodies), TA906 and TA919 (rimegepant), TA973 (atogepant)
Neurology: Headache and Facial Pain
Where it is discussed in the book
- Neurology: Anatomy, Physiology and Pharmacology (1 mention)
- Neurology: Headache and Facial Pain (2 mentions)